Images List Premium Download Classic

Endothelial Dysfunction

Endothelial Dysfunction-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Method and device for detecting and assessing reactive hyperemia using segmental plethysmography
Cordex Systems, Inc
February 15, 2018 - N°20180042490

A method for measuring reactive hyperemia in a subject is disclosed. The method includes performing a first segmental cuff plethysmography to generate a baseline arterial compliance curve and/or a baseline pressure-area (p-a) curve, performing a second segmental cuff plethysmography to generate a hyperemic arterial compliance curve and/or a hyperemic p-a curve, and calculating an area between the baseline ...
NEW Method and device for detecting and assessing reactive hyperemia using segmental plethysmography
Cordex Systems, Inc
February 15, 2018 - N°20180042489

A method for measuring reactive hyperemia in a subject is disclosed. The method includes performing a first segmental cuff plethysmography to generate a baseline arterial compliance curve and/or a baseline pressure-area (p-a) curve, performing a second segmental cuff plethysmography to generate a hyperemic arterial compliance curve and/or a hyperemic p-a curve, and calculating an area between the baseline ...
Long non-coding rna for the treatment of endothelial dysfunction
Johann Wolfgang Goethe-universität Frankfurt Am Main
January 25, 2018 - N°20180023080

The present invention associates multiplelong non-coding rna (lncrna) with key functions of endothelial cells. The lncrna of the present invention are therefore useful as novel drug targets for the manufacturing of medicines for the treatment of cardiovascular diseases or pathological angiogenesis in context of proliferative diseases such as cancer. Modulation of the function or expression of the lncrna of invention ...
Endothelial Dysfunction Patent Pack
Download + patent application PDFs
Endothelial Dysfunction Patent Applications
Download + Endothelial Dysfunction-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Endothelial Dysfunction-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Vasoprotective and cardioprotective antidiabetic therapy
Boehringer Ingelheim International Gmbh
November 30, 2017 - N°20170340643

The present invention relates to certain dpp-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such dpp-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.
Method for treating diseases associated with oxidative stress or endothelial dysfunction
November 16, 2017 - N°20170327466

Or an enantiomer, diastereomer, racemate, or a pharmaceutically acceptable salt of the compound.
Polyphenol compositions
Nugerontix Limited
August 03, 2017 - N°20170216245

The present application concerns polyphenol compositions, and the use of such compositions for preventing or treating endothelial dysfunction. The polyphenol compositions of the invention comprise at least one ellagitannin in combination with at least one proanthocyanidin.
Endothelial Dysfunction Patent Pack
Download + patent application PDFs
Endothelial Dysfunction Patent Applications
Download + Endothelial Dysfunction-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Endothelial Dysfunction-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method of therapy and diagnosis of endothelial dysfunction
Kaohsiung Medical University
April 06, 2017 - N°20170096666

The invention discloses a method of therapy of endothelial dysfunction, by administering microrna let-7g to a subject in need, wherein the microrna let-7g inhibits smad2 transcription factor from activation and translocation into nucleus, thereby decreasing monocyte cell adhesion, inflammation and thrombosis and increasing angiogenesis.
Methods for treatment of vascular endothelial dysfunction using nicotinamide mononucleotide
The Regents Of The University Of Colorado, A Body Corporate
March 30, 2017 - N°20170087171

This invention is about the compositions and methods for assessing and treating vascular endothelial dysfunction. Various aspects provide a method for treatment of vascular endothelial dysfunction, comprising administering a composition comprising nicotinamide mononucleotide and a pharmaceutical excipient to a subject. In one embodiment the dose is administered to subjects in response to the indicator. In another embodiment the dose is ...
Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
Purdue Research Foundation
February 16, 2017 - N°20170043023

Compositions and methods are provided for treating a patient suffering from a disease associated with endothelial dysfunction by administering to the patient a pharmaceutical composition containing an effective amount of a synthetic collagen binding peptidoglycan.
Dietary compositions for reducing blood glucose levels and for weight management
Marmar Investment Sp. Z O.o.
February 02, 2017 - N°20170028011

The present invention provides dietary compositions comprising mulberry extract, coffee extract, bean extract, optionally, dietary fibers, and a nutraceutically acceptable carrier. The present invention further provides methods for preventing the increase in postprandial hyperglycemia and hypoglycemia, hyperinsulinemia and diseases and disorders associated therewith, including, endothelial dysfunction, inflammatory conditions, oxidative stress, hyperlipidemia, and consecutive pathologies like insulin resistance, diabetes, visceral obesity, ...
Apolipoprotein a-i mimics
Cerenis Therapeutics Holding Sa
November 10, 2016 - N°20160324923

Provided are peptides, compositions thereof, and methods for treating or preventing dyslipidemia, a cardiovascular disease, endothelial dysfunction, a macrovascular disorder, or a microvascular disorder.
Combined agent for cell therapy of corneal endothelial cell
Senju Pharmaceutical Co., Ltd.
November 03, 2016 - N°20160317528

The present invention provides an agent for treating or preventing a disease, a disorder or a condition of a corneal endothelium, said agent comprising a corneal endothelial cell and a myosin ii-specific inhibitor. More specifically, the myosin ii-specific inhibitor is blebbistatin. The disease, the disorder or the condition is typically a disorder associated with fuchs endothelial corneal dystrophy or corneal ...
Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
Veroscience Llc
September 15, 2016 - N°20160263181

The present invention is directed to a method of treating a patient suffering from the metabolic syndrome and/or related disorders including obesity, type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, and comprising the steps of (a) providing to the patient a dietary regimen that decreases overactive cns noradrenergic tone; followed by (b) providing ...
Endothelial Dysfunction Patent Pack
Download + patent application PDFs
Endothelial Dysfunction Patent Applications
Download + Endothelial Dysfunction-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Endothelial Dysfunction-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Agonists of ddah1 for treating endothelial dysfunction
Ucl Business Plc
May 26, 2016 - N°20160145615

The present invention derives from the finding that expression of ddah1 is heavily post-transcriptionally regulated by micrornas. By preventing or blocking the interaction between such micrornas and the ddah1 mrna, the production of ddah1 protein can be increased. This has utility in the prevention or treatment of diseases and disorders that are associated with reduced ddah1 levels or increased adma ...
Methods of treating atherosclerosis
University Of Iowa Research Foundation
May 05, 2016 - N°20160122762

Certain embodiments of the invention provide a method of treating endothelial dysfunction, cardiovascular disease and/or atherosclerosis in a mammal, comprising administering an effective amount of a micro-rna-204-5p inhibitor to the mammal.
Molecular targets for cardiovascular disease
Temple University-of The Commonwealth System Of Higher Education
March 31, 2016 - N°20160089391

The invention relates to methods and compositions for treating and preventing cardiovascular disease, including but not limited to treating and preventing endothelial dysfunction in subjects having hyperhomocysteinemia, hyperglycemia, or a combination of hyperhomocysteinemia and hyperglycemia. As endothelial dysfunction is an indicator for atherosclerosis and cardiovascular disease, this treatment has general impact for early prevention and treatment for all cardiovascular disease. ...
Prodrugs of multifunctional nitroxide derivatives and uses thereof
Radikal Therapeutics Inc.
January 07, 2016 - N°20160002171

Prodrugs of compounds comprise a nitric oxide donor and a reactive oxygen species (ros) degradation catalyst, in particular, 1-pyrrolidinyloxy, 1-piperidinyloxy, and 1-azepanyloxy derivatives, and pharmaceutical compositions thereof. These compounds and pharmaceutical compositions are useful in prevention, treatment or management of diseases, disorders or conditions associated with oxidative stress or endothelial dysfunction.
Extracellular histones as biomarkers for prognosis and molecular targets for therapy
Oklahoma Medical Research Foundation
December 03, 2015 - N°20150344556

Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis. As such, they can be targeted pharmacologically by inhibitors, as well as used as biomarkers for prognosis of sepsis and other diseases.
Multifunctional nitroxide derivatives and uses thereof
Radikal Therapeutics Inc
November 26, 2015 - N°20150336932

Multifunctional nitroxide derivatives comprising a potassium channel opener and a reactive oxygen species (ros) degradation catalyst that can act as an anti-oxidant, as well as pharmaceutical compositions comprising them are provided. The multifunctional compounds and pharmaceutical compositions are useful for treatment of diseases, disorders or conditions associated with oxidative stress or endothelial dysfunction.
Compositions and methods for the treatment of metabolic diseases
October 15, 2015 - N°20150291590

The invention relates to the compounds of formula i, formula ii and formula iii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, formula ii or formula iii; and methods for treating or preventing metabolic diseases may be formulated for oral, buccal, ...
Synergistic anti-inflammatory compositions comprising boswellia serrata extract
October 15, 2015 - N°20150290270

The present invention discloses synergistic nutraceutical or pharmaceutical or dietary supplement anti-inflammatory compositions comprising therapeutically effective combination of an extract selectively enriched in 3-o-acetyl-1 1-keto-β-boswellic acid (akba) derived from boswellia serrata and boswellia serrata non-acidic resin extract (bnre). The composition(s) can be used to prevent, control and treat inflammation and several inflammatory related diseases including asthma, ...
Loading